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Abstract: 
Purpose. RayStretch is a simple algorithm proposed for heterogeneity corrections in low dose rate 
brachytherapy. It is built on top of TG-43 consensus data and it has been validated with Monte Carlo 
simulations. In this study, we take a real clinical prostate implant with seventy-one 125I seeds as 
reference and we apply RayStretch to analyze its performance in worst-case scenarios. 
 
Methods and Materials. To do so, we design two cases where large calcifications are located in the 
prostate lobules. RayStretch resilience under various calcification density values is also explored. 
Comparisons against Monte Carlo calculations are performed. 
 
Results. Dose-Volume Histogram related parameters like prostate D90, rectum D2cc, or urethra D10 
obtained with RayStretch agree within a few percent with the detailed Monte Carlo results for all 
cases considered. 
 
Conclusions. The robustness and compatibility of RayStretch with commercial treatment planning 
systems indicate its applicability in clinical practice for dosimetric corrections in prostate 
calcifications. Its use during intraoperative ultrasound planning is foreseen. 
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Introduction 
Permanent seed implants have become a common brachytherapy (BT) treatment for patients 
with low-risk prostate cancer [1] [2]. This medical technique involves the permanent placement of 
radioactive seeds in the prostate under ultrasound (US) guidance. The American Association of 
Physicists in Medicine (AAPM) task group No. 186 (TG-186), has recently emphasized the 
importance of properly incorporating tissue density and composition in a consistent manner [3]. This 
is more relevant in the case of low energy seeds, like the ones containing 125I, 103Pd, or 131Cs used in 
permanent BT implants. State-of-the-art Treatment Planning Systems (TPS) are able nowadays to 
take heterogeneities into account, in particular calcifications (accumulation of calcium within the 
prostate and therefore not water-equivalent), although only for high dose rate (HDR) 192Ir sources 
(see ref. [4] and references therein) and based on computed tomography (CT). The presence of such 
calcifications is a normal occurrence in males >50 years old [5]. 
Few clinical solutions exist that are able to fully, or partially, incorporate the dosimetric 
effect of calcifications in prostate BT implants in low-dose-rate (LDR) brachytherapy. Among them, 
Chibani and Williamson [6] proved for a 103Pd seed model using a dedicated Monte Carlo (MC) 
method that calcifications covering 1% − 5% of the prostate volume can reduce the value of D90 up 
to 37%.  
Taylor et al. [7] implemented a MC-based solution by developing a dedicated fast MC code, 
BrachyDose. For its application in clinical practice, including interseed attenuation and the presence 
of heterogeneities, BrachyDose forces every history to be recycled for all sources. Sutherland et al. 
[8] investigated the use of various breast tissue segmentation models including the presence of 
calcifications using BrachyDose for low-energy brachytherapy. Sutherland et al. [9] discussed 
various calcification modeling schemes for a LDR prostate brachytherapy patient using BrachyDose, 
highlighting the importance of detailed and accurate calcification modelling. 
An initiative to address the presence of calcifications was developed by Mashouf et al. [10]. 
In this work, inhomogeneity corrections factors (ICF) were derived for the case of 103Pd breast BT. 
The agreement between MC simulations and the ICF method remained within 5% in soft tissues up 
to several centimetres from a 103Pd seed. In another publication, Mashouf et al. [11] expanded that 
study to make use of dual energy CT images to extract the ICF in a phantom. The results were also 
compared to experimental measurements using radiochromic films. The authors concluded that for 
the case of an implant configuration of 8 seeds spaced 1.5 cm apart in a cubic structure, the gamma 
index (2%/2 mm) criteria improved from 40.8% to 90.5%.   
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In Fekete et al. [12], the role played by the presence of heterogeneities in the prostate was 
discussed. Geant4 MC simulations were made following TG-186 recommendations. Different 
scenarios were presented including the case of dose to medium in medium as compared to dose to 
water in medium. The authors concluded that calcifications alter the dose coverage and may result in 
severe dose perturbation that may require recalculation. 
Bonenfant et al. [13] improved the physics library included in bGPUMCD, a MC algorithm 
executed on Graphics Processing Units, for fast dose calculations in permanent prostate implant 
dosimetry.  For permanent prostate implants, MC-based dosimetric indices were obtained in 30 s 
with differences within 2.7% with respect to an independent and validated MC code (Geant4). 
Pope et al. [14] investigated the effect of prostatic calcifications on brachytherapy treatments 
by means of MC calculations. Calcification samples were characterized with micro-particle induced 
X-ray emission to determine their heavy element composition. Clinical brachytherapy treatments 
were modelled using MC calculations. Dose reductions were observed to be up to 30% locally to the 
calcification boundary, calcification size dependent. Single large calcifications and closely placed 
calculi caused local dose reductions of 30% – 60%. Dosimetric parameters like prostate D90 showed 
a reduction of 2% – 5%, regardless of calcification surface area and volume. The parameters V100, 
V150 and V200 were also reduced by as much as 3% and on average by 1%. It should be noted that 
Pope et al were not able to reproduce the results reported by Chibani and Williamson. 
Miksys et al. [15] have recently published a retrospective study between water-based and full 
tissue model Monte Carlo dose calculations in a large cohort of patients undergoing I-125 permanent 
implant prostate brachytherapy. The MC code EGSnrc BrachyDose was employed to analyze  613 
patients using two virtual patient models, one TG43-based and one including CT-derived 
heterogeneous tissue composition and interseed effect. Among other effects, they reported that 
patients with prostate calcifications can have substantial underdosed volumes due to calcification 
shielding, lowering the D90 value up to 25%. 
 In 2015, an analytical algorithm designed to account for the presence of calcifications in LDR 
prostate brachytherapy treatments, RayStretch, was developed by Hueso-Gonzalez et al. [16]. The 
MC simulations performed there showed a good agreement with the algorithm for the case of a 
single seed position. Anatomic details from a real patient with calcifications were obtained from a 
CT image. In this study, we aim to benchmark RayStretch in a real clinical 125I seeds prostate 
implant. Therefore, the main goals of this study are: 
1. To benchmark RayStretch against a detailed MC simulation in a realistic clinical case. 
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2. To evaluate the resilience of RayStretch to accurately estimate dose for two large prostate 
calcification volumes and three densities. Those configurations are to be considered worst-
case scenarios. 
3. To measure the calculation time of RayStretch for a realistic implant and voxel grid. 
4. To assess the next steps towards the implementation of RayStretch in intraoperative 
ultrasound planning. 
 




A full discussion on the RayStretch algorithm can be found in Hueso-Gonzalez et al. [16]. 
Nevertheless, for the sake of completeness, we discuss its main characteristics in the following. 
RayStretch is an algorithm based on the TG-43 formalism [17], able to accommodate the existence 
of calcifications in the prostate. Therefore, effects like interseed attenuation are not taken into 
account. To do so, an effective radial dose function geq(r) is evaluated from the TG-43 consensus 
radial dose function gP(r) already incorporated into the TPS. In doing so, minimal modifications in 
the TPS will be required to implement RayStretch in clinical practice.  
The effective radial dose function is evaluated making use of an effective distance 
constructed assuming that the energy deposited along a path rcal inside a calcification would have 
been deposited along a longer path rcal,eq in water, i.e. if the calcification were absent. Therefore, to 
define the effective distance rcal,eq = λ rcal, a scaling parameter 𝝀𝝀 =
µ𝑪𝑪𝑪𝑪
µ𝒘𝒘
 is required, where µ stands for 
the linear attenuation coefficient, Ca for the calcification and w for water. This parameter has to be 
adjusted empirically by comparing the algorithm with a MC simulation where a particular seed and 
calcification composition is established beforehand. An empirical value 𝝀𝝀 = 𝟓𝟓.𝟑𝟑 was used in Hueso-
Gonzalez et al. [16] and in the following. Thus, the simplified recipe for applying the algorithm 
becomes: 
 
𝒓𝒓𝒆𝒆𝒆𝒆(𝒓𝒓) = 𝒓𝒓𝒘𝒘 + 𝝀𝝀 𝒓𝒓𝒄𝒄𝑪𝑪𝒄𝒄 ,    (1) 
 
where r is the real distance between seed and calculation point, rw is the subsegment of r crossing 
water and rcal the part inside a calcification. Depending on whether the calculation voxel is inside or 
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  (2) 
 
where 𝒈𝒈𝒆𝒆𝒆𝒆 refers to the effective radial dose function and 𝒈𝒈𝒘𝒘 to the TG-43 radial dose function gP(r)  
consensus data of the seed considered. See Hueso-Gonzalez et al. [16] for a detailed discussion on 
how the effective radial dose function is evaluated. Thus, RayStretch requires just a minimum 
modification of the current TG-43 based TPS. It should be noted that voxels are assigned to either 
water or calcification, whatever is the largest in the voxels. Therefore, no mixed voxels are 
considered. 
The 125I 6711-OncoSeed™ seed was chosen to create the current working implementation of 
RayStretch because it was the most widely used worldwide until January 2017. While no longer 
available, the impact of this work is relevant as there are many seeds whose design is very similar to 
such model.  
To our knowledge, calcification composition is not a subject that has been widely analyzed in 
the literature. Therefore, in Hueso-Gonzalez et al. [16] a standard composition by weight was 
considered for the calcification: H(5.6%), C(26.5%), N(3.6%), O(40.5%), Na(0.1%), Mg(0.2%), 
P(7.3%), S(0.3%) and Ca(15.9%). Such composition corresponds to a standard calcium-rich material 
with Hounsdfield numbers in the range 800-900 [18]. For this particular composition, solid objects 
have densities of the order of 1.5 g/cm3 (see Fig 9 in Ref. [18]). Therefore, we assumed that as an 
upper limit for the possible density values. It should be emphasized that RayStretch has not been 
designed to manage tissue composition differences in the way MC does. Its purpose is to improve 
LDR implant dosimetry by using modified TG-43 consensus data. Then, its implementation in 
current TPSs will require simple modifications. In this way it can be used during the implant 




In this work we have applied RayStretch to a clinical LDR prostate implant provided by the 
University and Polytechnic Hospital La Fe. For this implant 71 6711-OncoSeedTM seeds divided in 
15 catheters were used. Their planned source strength was 0.662 U for a total prescribed dose of 160 
Gy. It is to note that this prescription dose is in contrast to societal guidelines which recommend a 
prescription dose of 144/145 Gy [1] [2]. Contouring of all organs as defined by the radiation 
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oncologist was also included in the plan. The prostate had a volume of 45.2 cm3 and the MC-
evaluated prostate D90 was 108%. The rectum had a D2cc of 73% and the urethra a D10 of 118%. 
Being a realistic clinical implant, it followed the clinical recommendations established by 
ESTRO/EAU/EORTC [1] that we briefly summarize here for the sake of completeness: i) The 
prescribed dose will be in the range 140 Gy – 160 Gy where D90 will be in the range 90% – 130%, ii) 
D2cc in the rectum ≤ 100 % reference prescription dose, and iii) D10 in the urethra ≤ 150 % reference 
prescription dose. According to the Radiation Therapy Oncology Group Protocol 0232 [19], 
variations of prostate D90 in the range 80% – 90% or larger than 130% will be deemed acceptable 
while values lower than 80% will be considered unacceptable, being considered a Medical Event. 
The possibility of using CT images to obtain the mass density of each voxel and to include 
this information into RayStretch was studied in Hueso-Gonzalez et al. [16]. In this work, we have 
preferred to explore the compliance and robustness of RayStretch in clinical conditions by 
contouring artificial calcifications in the prostate. Our aim is to benchmark RayStretch performance 
in worst-case scenarios, where the prostate contains large calcifications in the most probable 






Figure 1. Figure (a) corresponds to Case A and Figure (b) to Case B. Voxelized 
reconstruction of the prostate (transparent blue), rectum (red), urethra (brown), and 
calcifications (blue) volumes. The organ segmentation is based on US planning and the 
voxels have been determined by a home-made automatic segmentation algorithm as described 
in the text. 
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- Case A, Figure 1a, made of two ellipsoidal calcifications, covering 11% of prostate volume, 
and mainly located in the posterior lobes. This choice is motivated by the frequent 
localization of calcifications close to the apex in prostate patients.  
- Case B, Figure 1b, is formed by three ellipsoidal calcifications, occupying 30% of the target 
volume, and situated both in the posterior lobes and close to the prostate apex.  
 
Additionally, three mass densities have been chosen for the calcified region, 1.05, 1.20, and 
1.35 g/cm3, labeled as I, II and III, respectively. The calcification composition has not been altered in 
any case. Therefore, 6 different cases (AI, AII, AIII, BI, BII, BIII) ranging from small low density 
calcifications to large high density ones are explored to test RayStretch even in worst case scenarios. 
The extreme cases AIII and BIII are particularly interesting, as the knowledge about 
inadequate dosimetry inherent to TG-43 in these cases may persuade physicians to not recommend 
this type of patients for LDR prostate BT. This is the case at the University and Polytechnic Hospital 
La Fe, where a patient falling into Case BIII will not be considered for LDR brachytherapy treatment 
due to the presence of such extended calcifications, independently of whether the treatment would be 
advisable for this tumoral lesion. This patient is then treated using HDR 192Ir BT in two fractions. 
 
Monte Carlo simulation 
 
A comprehensive description of the MC simulation and code are given in Hueso-Gonzalez et 
al. [16], hence we only briefly summarize here its main details. The 6711-OncoSeed™ seed consists 
of a 4.5 mm welded titanium capsule, 0.05 mm thick, with welded end caps. The capsule contains a 
2.8 mm long silver rod onto which 125I (mixture of AgBr and AgI in a 2.5:1 molecular ratio) is 
deposited. A full description of its geometry and TG-43 parameters can be found in Dolan et al. [20].  
Penelope2008, a MC code whose reliability and performance have been widely tested [21] 
has been used in this work. Further information on this software can be found elsewhere [22], [23]. 
Benchmark simulations have been performed comparing the latest Penelope2011 version with 
respect to the 2008 version used in the following and negligible differences have been observed. 
Collisional kerma using home-made routines and absorbed dose have been evaluated in a 
Cartesian grid of 61×61×46 voxels, each with a volume of 1 mm3, for the six scenarios described 
above (Case AI to Case BIII) plus TG-43 conditions (water phantom with no calcifications). Since 
RayStretch does not take into account interseed attenuation, that effect has not been considered in the 
simulations. 
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To speed up the simulation, the photon spectrum leaving the encapsulation of a single seed 
submerged in water was scored and then emitted isotropically from each one of the positions where 
the TPS positioned a seed. For the total implant N=109 histories were simulated for each seed (Type 
A uncertainty of 1.6% (k=2) for each seed), that will produce a total statistic of N=7.1×1010 histories 
and an average Type A uncertainty of 0.2% (k=2). This approach allows us to greatly reduce the 
simulation time at the expense of neglecting dose differences close to the source due to its geometry.  
To flag each voxel as belonging to a particular organ at risk (OAR) or the target, a home-
made software has been developed to automatically segment the DICOM file for use in RayStretch 
and the MC calculation. To do so, a voxel is assigned to a given volume when its center is inside the 
contour. This particular criterion might differ for a given TPS, and therefore some small 
discrepancies might appear in the case of small organs. 
 
Results and Discussion 
 
As explained above, Raystretch makes use of the TG-43 consensus dataset for the 6711 seed. 
These datasets do not vary much when a different seed model with similar design is chosen, hence no 
different results are expected for other similar 125I seeds. 
 
An example of the dose delivered to each voxel in a particular slice of the grid is shown in 
Figure 2 for the Case AI (small, low density calcifications). As expected, the TG-43 (homogeneous 
case) does not take into account the effect on the dosimetry caused by the presence of calcified 
regions. To illustrate the accuracy of RayStretch, we depict in Fig. 2(d) its ratio with respect to MC. 
Large differences are expected very close to the seed, see discussion below. We show a rebinned 
histogram using 4 mm × 4 mm voxels. The similarity between RayStretch and the MC simulation is 
qualitatively visible for the majority of voxels (excluding those close to the seeds, marked as red 
dots). The same pattern can be found in all slices and cases. On a more quantitative perspective, the 
Dose-Volume Histogram (DVH) parameters are compared in Figure 3 for the six cases and 
calculation methods. Values of prostate D90, rectum D2cc and urethra D10 are also given in Table 1. 
Differences due to the use of absorbed dose or kerma are less than 0.5% in all cases. In Figure 3 all 
DVHs listed as TG-43 data correspond to the values given by RayStretch in TG-43 conditions, i.e., 










Figure 2. (a): Transverse slice of the patient corresponding to Case AI showing the organ 
segmentation and the actual seed implant. Seeds are depicted as red dots. (b): Dose 
calculated for this transverse slice using the TG-43 formalism (all water). (c): Same using 
RayStretch (RS). (d): Dose ratios between RayStretch and MC (2D histogram rebinned to 4 




 (a)  (d) 
 (b)  (e) 
 (c)  (f) 
Figure 3. DVH for Case A (left panels, small calcification with low (a), medium (b) and high (c) 
densities) and Case B (right panels, large calcification with low (d), medium (e) and high (f) 
densities) in TG-43 conditions evaluated using RayStretch, see text for details (dotted line); the MC 
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calculation (dashed line) and the RayStretch algorithm (solid line) for all three calcification densities 
and organs: prostate (blue), rectum (orange lines), and urethra (green). Dref stands for the total 
prescribed dose of 160 Gy. 
 
 
Table 1. Values of prostate D90, rectum D2cc, and urethra D10 (as % of the 160 Gy prescribed dose) 
for the six cases analyzed (AI to BIII) and also for TG-43 conditions (unbounded water phantom 
with no calcifications). RS corresponds to the values obtained with RayStretch and MC for the MC 
calculation. 
 D90 Prostate (%) D2cc Rectum (%) D10 Urethra (%) 
Method RS 1-RS/MC RS 1-RS/MC RS 1-RS/MC 
TG-43 110 1.8 69 5.5 116 1.7 
AI 94 0.0 61 4.7 94 1.0 
AII 92 0.0 61 3.2 93 1.1 
AIII 90 1.1 60 4.8 90 2.2 
BI 80 1.2 51 3.8 79 1.2 
BII 78 1.3 49 3.9 77 1.3 
BIII 76 2.6 48 4.0 76 1.3 
 
 
The prostate D90 decreases more than 10 percentage points in all cases with respect to the 
homogeneous TG-43 case. Some cases (BIII) are low enough to be deemed unacceptable by RTOG 
Protocol 0232 and even flagged as a Medical Event. Prostate D90 results given by the full MC 
calculation agree within an average value of 1.0% (range 0.0% – 2.6%) with the RayStretch 
algorithm. With respect to rectum D2cc, the differences are in the range 3.2% – 4.7%, averaging 
4.1%, while for the urethra D10 the range becomes 1.0% – 2.2% and its average discrepancy 1.3%. 
These results allow us to establish a confidence level of 1% – 4% for RayStretch in reproducing a 
clinical plan.  
The main source of these differences can be traced back to two different issues. On one hand, 
the implementation of the automatic segmentation algorithm chosen might differ from the one used 
in the MC calculation, especially for those organs close to the DICOM anatomical structure borders 
or for small ones, hence the numbers of voxels assigned to the organs may vary slightly. On the other 
hand, seeds positions in MC are exactly those given by the TPS in the planning system. The current 
implementation of RayStretch rounds this seed position to the center of the closest voxel. Thus, dose 
discrepancies between RayStrecth and MC are expected in the seed vicinity. 
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By analyzing a density range of 1.05 g/cm3 to 1.35 g/cm3 and different calcification volumes 
(10% – 30% of the prostate) one can evaluate the resilience of RayStretch when dealing with 
different clinical conditions. As it can be observed in Table 1, the quality of the comparison between 
MC and RayStretch does not degrade when deviating further from TG-43 conditions, either by 
increasing the density (I→III) or the calcification volume (A→B). This suggests the ability of 
RayStretch to accurately estimate dose for a variety of clinical situations. 
With respect to numerical efficiency, although no expert computing effort has been made to 
improve RayStretch numerical performance, its present implementation is able to evaluate a full 
implant in less than 25 seconds on a personal computer. An effort in reducing this computational 
time to obtain sub-second performance is underway.  
Finally, future steps on the road towards clinical translation are: 
• To test the robustness of RayStretch with other types of LDR seeds (103Pd, 131Cs). 
• To include air cavities as a second type of heterogeneity in the algorithm. 
• To perform US-based tissue segmentation (input data for RayStretch). The volumes 
determined as regions of interest from a CT performed before the implant together with the 
average electronic densities (obtained from the Hounsfield numbers) have to be registered 
with real time US images used during the intraoperative procedure. The uncertainty in the 




RayStretch is an analytical but robust algorithm for heterogeneity corrections in prostate BT. 
It has been tested using a realistic clinical prostate 125I implant including virtual calcifications, 
benchmarking RayStretch against worst-case scenarios. The results for DVH-related parameters 
agree with complete MC calculations within an average of 1.0% for prostate D90, 4.1% for rectum 
D2cc and 1.3% for urethra D10. This allow us to establish a confidence level of 1% – 4% for 
RayStretch in reproducing a clinical plan. In contrast to sub-minute MC simulations, RayStretch is 
based on TG-43 consensus data and simplified tissue segmentation. Thus, it has the potential to be 
easily implemented in commercial TPSs with minor efforts and software modifications. Its high 
calculation speed opens up the horizon of dose recalculation in real-time intraoperative treatment 
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